van der Burg SH - Search Results

1

The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.

de Vos van Steenwijk PJ, van Poelgeest MI, Ramwadhdoebe TH, Löwik MJ, Berends-van der Meer DM, van der Minne CE, Loof NM, Stynenbosch LF, Fathers LM, Valentijn AR, Oostendorp J, Osse EM, Fleuren GJ, Nooij L, Kagie MJ, Hellebrekers BW, Melief CJ, Welters MJ, van der Burg SH, Kenter GG. de Vos van Steenwijk PJ, et al. Among authors: van der burg sh, van der minne ce, van poelgeest mi. Cancer Immunol Immunother. 2014 Feb;63(2):147-60. doi: 10.1007/s00262-013-1499-2. Epub 2013 Nov 15. Cancer Immunol Immunother. 2014. PMID: 24233343 Free PMC article. Clinical Trial.

2

Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.

van Elsas A, van der Burg SH, van der Minne CE, Borghi M, Mourer JS, Melief CJ, Schrier PI. van Elsas A, et al. Among authors: van der burg sh, van der minne ce. Eur J Immunol. 1996 Aug;26(8):1683-9. doi: 10.1002/eji.1830260803. Eur J Immunol. 1996. PMID: 8765006

3

Design and evaluation of antigen-specific vaccination strategies against cancer.

Offringa R, van der Burg SH, Ossendorp F, Toes RE, Melief CJ. Offringa R, et al. Among authors: van der burg sh. Curr Opin Immunol. 2000 Oct;12(5):576-82. doi: 10.1016/s0952-7915(00)00145-x. Curr Opin Immunol. 2000. PMID: 11007362 Review.

4

Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes.

van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken KL, Ottenhoff TH, Fleuren GJ, Kenter G, Melief CJ, Offringa R. van der Burg SH, et al. Among authors: van meijgaarden ke. Int J Cancer. 2001 Mar 1;91(5):612-8. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1119>3.0.co;2-c. Int J Cancer. 2001. PMID: 11267969 Free article.

5

Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens.

van der Burg SH, Kwappenberg KM, O'Neill T, Brandt RM, Melief CJ, Hickling JK, Offringa R. van der Burg SH, et al. Vaccine. 2001 Jun 14;19(27):3652-60. doi: 10.1016/s0264-410x(01)00086-x. Vaccine. 2001. PMID: 11395199

6

Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects.

de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P, Melief CJ, Offringa R. de Jong A, et al. Among authors: van meijgaarden ke, van der hulst jm, van der burg sh. Cancer Res. 2002 Jan 15;62(2):472-9. Cancer Res. 2002. PMID: 11809698

7

Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.

van der Burg SH, Menon AG, Redeker A, Bonnet MC, Drijfhout JW, Tollenaar RA, van de Velde CJ, Moingeon P, Kuppen PJ, Offringa R, Melief CJ. van der Burg SH, et al. Among authors: van de velde cj. Clin Cancer Res. 2002 May;8(5):1019-27. Clin Cancer Res. 2002. PMID: 12006514 Clinical Trial.

8

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.

Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJ. Zwaveling S, et al. Among authors: van der burg sh. J Immunol. 2002 Jul 1;169(1):350-8. doi: 10.4049/jimmunol.169.1.350. J Immunol. 2002. PMID: 12077264

9

Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.

Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R. Melief CJ, et al. Among authors: van der burg sh. Immunol Rev. 2002 Oct;188:177-82. doi: 10.1034/j.1600-065x.2002.18816.x. Immunol Rev. 2002. PMID: 12445291

10

The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development.

van der Burg SH, de Jong A, Welters MJ, Offringa R, Melief CJ. van der Burg SH, et al. Virus Res. 2002 Nov;89(2):275-84. doi: 10.1016/s0168-1702(02)00196-x. Virus Res. 2002. PMID: 12445667 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

344 results

Search Page